R&G PharmaStudies Co., Ltd. (SHE:301333)

R&G PharmaStudies Revenue

R&G PharmaStudies had revenue of 249.87M CNY in the quarter ending June 30, 2026, with 20.81% growth. This brings the company's revenue in the last twelve months to 939.31M, up 26.14% year-over-year. In the year 2025, R&G PharmaStudies had annual revenue of 851.01M with 14.38% growth. That makes R&G PharmaStudies the 20,091st largest company in the world by revenue and 3,681st in China.

• Revenue (ttm): 939.31M
• Revenue Growth: +26.14%
• P/S Ratio: 6.24
• Revenue / Employee: 355.13K
• Employees: 2,645
• Market Cap: 5.86B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	851.01M	107.00M	14.38%
Dec 31, 2024	744.00M	22.63M	3.14%
Dec 31, 2023	721.37M	83.85M	13.15%
Jan 1, 2023	637.52M	29.09M	4.78%
Jan 1, 2022	608.43M	123.98M	25.59%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 9, 2026

Data Sources Report a data error